Matrine impedes colorectal cancer proliferation and migration by downregulating endoplasmic reticulum lipid raft associated protein 1 expression. Issue 4 (1st April 2022)

• Record Type: Journal Article
• Authors: Ren, Hongtao; Wang, Yali; Guo, Ya; Wang, Mincong; Ma, Xiulong; Li, Wen; Guo, Yuyan; Li, Yiming
• Is Part Of: Bioengineered. Volume 13:Issue 4(2022)
• Page Start: 9780
• Page End: 9791
• Publication Date: 2022-04-01
• Subjects: Matrine -- Erlin1 -- anti-tumor -- proliferation -- progression; Biomedical engineering -- Periodicals; Biotechnology -- Periodicals; Microbiology -- Periodicals; 660.6
• DOI: 10.1080/21655979.2022.2060777
• Languages: English
• ISSNs: 2165-5987

Abstract

ABSTRACT: Matrine exhibits anti-tumor effect on the proliferation and invasion of colorectal cancer (CRC) cells by reducing the activity of the p38 signaling pathway. However, these studies were limited because the underlying mechanism by which matrine inhibited CRC progression remained unclear. In this study, we provided for the first time that endoplasmic reticulum lipid raft associated protein 1 (Erlin1) is a novel target of matrine. Erlin1 was significantly upregulated in tumors and its knockdown suppressed the proliferation and migration of CRC cells, while its overexpression promoted CRC cell growth and migration. Furthermore, Erlin1 overexpression promoted inhibited apoptosis. Importantly, matrine treatment could reverse the oncogenic function of Erlin1 on CRC cell proliferation and migration. When Erlin1 was knocked down, matrine exhibited a more obvious anti-tumor effect in CRC cells. Partly due to this, matrine functions as an important anti-tumor drug and the results discovered here may clarify the mechanisms of matrine application for CRC treatment. CRC patients with low expression of Erlin1 might be more suitable for the treatment of matrine. This study could promote the application of matrine to be a promising therapeutic strategy for CRC patients. Graphical abstract: uf0001